Microalbuminuria prevalence study (MAPS) in hypertensive type 2 diabetic patients in Hong Kong

Hong Kong Medical Journal

Volumn 12, Issue 3, 2006, Pages 185-190

  Yeung, V T F ^a   Lee, K F ^b   Chan, S H ^c   Ho, L F ^c   Leung, S K ^c   Wong, H Y ^c  

^a Our Lady of Maryknoll Hospital   (Hong Kong)

^b KWONG WAH HOSPITAL   (Hong Kong)

^c NONE

Author keywords

Albuminuria; Diabetes mellitus, type 2; Diabetic nephropathies; Hypertension; Renin angiotensin system

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGE; ARTICLE; BACTERIURIA; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATURIA; HONG KONG; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT DEPARTMENT; PREDICTOR VARIABLE; PUBLIC HEALTH; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HONG KONG; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE;

EID: 33745260423     PISSN: 10242708     EISSN: 10242708     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992;19:403-18.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-44.
3. Diabetes e-Atlas. International Diabetes Foundation website: http://www.idf.org/e-atlas/home/. Accessed 6 Jan 2004.
4. Chan JC, Cheung CK, Cheung MY, Swaminathan R, Critchley JA, Cockram CS. Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care 1995;18:1013-6.
5. Ho YW, Chau KF, Leung CB, et al. Hong Kong Registry Report 2004. Hong Kong J Nephrol 2005;7:38-46.
6. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-60.
7. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-8.
8. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996;27:2033-9.
9. American Diabetes Association. Diabetic nephropathy. Position statement. Diabetes Care 2002;25(Suppl 1):85S-89S.
10. Spooren PF, Lekkerkerker JF, Vermes I. Micral-Test: a qualitative dipstick test for micro-albuminuria. Diabetes Res Clin Pract 1992; 18:83-7.
11. Mather HM, Chaturvedi N, Kehely AM. Comparison of prevalence and risk factors for microalbuminuria in South Asians and Europeans with type 2 diabetes mellitus. Diabet Med 1998;15:672-7.
12. Tomura S, Kawada K, Saito K, et al. Prevalence of microalbuminuria and relationship to the risk of cardiovascular disease in the Japanese population. Am J Nephrol 1999;19:13-20.
13. Tam TK, Cheng LP, Lau DM, et al. The prevalence of microalbuminuria among patients with type II diabetes mellitus in a primary care setting: cross-sectional study. Hong Kong Med J 2004;10:307-11.
14. Wu AY, Kong NC, de Leon FA, et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetes patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005;48: 17-26.
15. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-83.
16. Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int 2001;60:2041-55.
17. Chan JC, Cheung CK, Swaminathan R, Nicholls MG, Cockram CS. Obesity, albuminuria and hypertension among Hong Kong Chinese with non-insulin-dependent diabetes mellitus (NIDDM). Postgrad Med J 1993;69:204-10.
18. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
19. Cooper ME, Frauman A, O'Brien RC, Seeman E, Murray RM, Jerums G. Progression of proteinuria in type 1 and type 2 diabetes. Diabet Med 1988;5:361-8. Erratum in: Diabetic Med 1988;5:422.
20. Ritz E, Tarng DC. Renal disease in type 2 diabetes. Nephrol Dial Transplant 2001;16(Suppl 5):11S-18S.
21. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl 2):14S-21S.
22. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. Erratum in: JAMA 2003;290:197.
23. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13. Erratum in: BMJ 1999;318:29.
24. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
25. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9. Erratum in: Lancet 2000;356:860.
26. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
27. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
28. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
29. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61.